论文部分内容阅读
目的评价血清VEGF在恶性肿瘤患者治疗中的临床价值。方法对337例未经治疗的恶性肿瘤患者、25例术后及22例术后复发的恶性肿瘤患者应用ELISA法进行了血清VEGF含量及阳性率检测,并以47例良性肿瘤及61例健康成人作为对照组。结果恶性肿瘤患者血清VEGF含量及阳性率明显高于健康对照组及良性肿瘤组(P<0.001),宫颈癌患者术后7￣10d较术前明显增高(P<0.02),术后1￣2个月恶性肿瘤患者较术前明显下降(P<0.001),而术后复发者又显著上升(P>0.05)。结论监测恶性肿瘤患者血清VEGF的动态变化有助于了解患者病情的发展。
Objective To evaluate the clinical value of serum VEGF in the treatment of malignant tumor patients. Methods 337 cases of untreated malignant tumor patients, 25 cases of postoperative and 22 cases of recurrent malignant tumor patients using ELISA method for serum VEGF levels and positive rate detection, and 47 cases of benign tumors and 61 healthy adults As a control group. Results The serum VEGF level and positive rate in patients with malignant tumor were significantly higher than those in healthy control group and benign tumor group (P <0.001). Cervical cancer patients were significantly higher (P <0.02) 7 ~ 10d after operation than that before operation The number of malignant tumor patients in one month was significantly lower than that before operation (P <0.001), while the recurrence after operation was significantly higher (P> 0.05). Conclusion The dynamic changes of serum VEGF in patients with malignant tumors can help to understand the development of the patients’ condition.